USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Technology Innovations and Growth Opportunities in Inhaled Therapeutics
Technology Innovations and Growth Opportunities in Inhaled Therapeutics
Nanoparticle-based Formulation to Drive Transformational Growth Across Inhaled Vaccines and Monoclonal Antibodies
27-Apr-2023
Global
Description
Inhalation drug delivery involves administering drugs to the lungs through the mouth (pulmonary route) or nose (intranasal route), enabling them to bypass the blood-brain barrier. Small molecules have been the main focus for inhalation delivery, but recent R&D and increased interest in inhalable COVID-19 vaccines have led to a shift toward inhalable biologics for conditions where injection delivery is the norm.
This Frost & Sullivan study highlights important formulations for inhalable biologics and examines the factors that drive or limit market growth. The research examines the pipeline of monoclonal antibodies and vaccines in development and evaluates R&D trends, partnership and collaboration trends, funding and investment analysis, patent analysis, and the outlook for inhalable biologics. The study identifies significant growth opportunities for industry players in the field.
Questions this study answers:
1. What factors drive or limit the industry’s growth?
2. What are the innovative methods for formulating inhalable biologics?
3. What does the pipeline analysis for inhalable vaccines and monoclonal antibodies look like?
4. What are the R&D trends and projected developments of the technologies?
5. What are the funding evaluations, patent evaluations, regulatory environments, and trends for partnerships and collaborations for inhalable biologics?
6. What are the growth opportunities for technology developers in the inhalable biologics space?
Table of Contents
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Inhaled Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Scope of Analysis
The Need for Inhalation Biologics Formulation
Inhalation Drug Delivery—Introduction
Segmentation—Formulations for Drug Inhalation
Pros and Cons of Formulation and Drug Delivery Systems for Inhalation
Examples of Novel Formulations and Drug Delivery System for Inhalable Biologics
Promising Inhalation Therapy—Advantages of Inhalational Monoclonal Antibodies (mAbs) and Vaccines
Growth Drivers
Growth Restraints
Pipeline Analysis of Inhaled Vaccines and mAbs
Vaccines and mAbs under Clinical Development
Primary Technologies—AttenuBlock Platform Technology (Codon Deoptimization for Live Attenuated Vaccine Candidates)
Primary Technologies—Nanoemulsion Platform (Intranasal Adjuvant Technology)
R&D Trends
Collaboration and Partnership Trends
Funding and Investment Analysis
Patent Analysis
Future Roadmap
Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution
Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution (continued)
Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services
Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services (continued)
Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration
Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration (continued)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
| Author | Ashish Kaul |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Inhalable Drugs Market |
| Keyword 2 | Inhaled Therapeutics Market |
| Keyword 3 | Lung Disease Therapeutics Market |
| Podcast | No |
| WIP Number | DA9D-01-00-00-00 |